RNA-based Cancer Vaccine Development Services
The COVID-19 pandemic has brought mRNA-based vaccines, which can serve as effective carriers for the delivery of therapeutic antibodies to immune targets, to the forefront of global attention. As a result, RNA is gaining popularity in cancer immunotherapy. Alfa Cytology offers a one-stop shop from gene synthesis to RNA synthesis to deliver high-quality RNA cancer vaccines for your research.
Introduction to RNA Vaccine
RNA vaccines stimulate an immune response by delivering antigens to immune cells. This approach is highly effective in generating a robust immune response. These antigens are designed to synthesize exogenous proteins produced by pathogens, such as viruses, or cancer cells based on the designed RNAs. The process initiates a highly effective adaptive immune response, enabling the body to accurately identify and eliminate the targeted pathogen or cancer cell.
Fig.1 mRNA-based vaccine mode of action (Lorentzen, C. L, et al., 2018)
Advantages of RNA Cancer Vaccines
Advances in RNA-based cancer vaccines have revolutionized the field of cancer immunotherapy. RNA cancer vaccines offer the following advantages.
- Personalization
RNA vaccines are highly personalized because they can encode antigens specific to different tumors. - Safety
Because RNA vaccines do not contain living viruses or tumor cells, there is a very low risk of infection or other common side effects. - Flexibility
The RNA platform allows for rapid development and modification of vaccines to target different types of cancer or include multiple antigens, increasing their versatility and adaptability to various tumor profiles.
Our Service
Our expertise in RNA vaccine synthesis from DNA templates ensures precision and success, directly impacting downstream transcription and expression efficiency. Alfa Cytology provides a comprehensive solution to deliver high-quality RNA cancer vaccines efficiently and promptly to support your research. Our range of RNA vaccines includes investigational to preclinical levels, and there are many types of vaccine delivery systems for you to choose from.
RNA Cancer Vaccine Development Process
RNA cancer vaccines represent cutting-edge therapeutic strategies leveraging RNA technology to activate the patient's immune system against cancer cells. With various types available, Alfa Cytology offers specialized RNA vaccine development services tailored to your needs.
Target Selection
Cancer-associated antigens or tumor-associated antigens are identified through genomic and proteomic studies of cancer cells.
Design
Design of RNA sequences, selection of appropriate RNA sequences, and incorporation of appropriate auxiliary elements to enhance RNA stability and translation efficiency.
Synthesize
Synthesis of designed RNA sequences by chemical synthesis or in vitro transcription
Packaging
Synthesized RNA undergoes appropriate packaging to enhance its stability and delivery efficiency in vivo, often through methods such as liposomes or polymer nanoparticles.
Preclinical Studies
Preclinical studies of RNA cancer vaccines in laboratory and animal models evaluate safety, immunogenicity, and antitumor efficacy.
Why Choose Us?
Professional and well-trained technical team.
Advanced experimental equipment.
Empowering success through cooperation.
Strict quality control system.
Alfa Cytology offers comprehensive solutions tailored to your project's requirements. Our team of seasoned professionals specializes in analyzing your project's specific needs and developing optimized approaches to ensure high-quality and timely delivery. From gene summarization to RNA-based cancer vaccine development services, we cover every step of the process. Our experienced team will guide you through designing RNA cancer vaccines, providing various options to meet your research needs effectively. Contact us to discover more about our services and how we can assist you.
Reference
- Palmer, C. D., et al.; (2022). Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nature medicine, 28(8), 1619–1629. https://doi.org/10.1038/s41591-022-01937-6